Skip to content

Negative Pressure Wound Therapy for Surgical Site Infection Prevention in Common Femoral Artery Exposure

Negative Pressure Wound Therapy for Surgical Site Infection Prevention in Vascular Surgery Patients Undergoing Common Femoral Artery Exposure

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03935659
Enrollment
0
Registered
2019-05-02
Start date
2018-03-26
Completion date
2021-10-01
Last updated
2021-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Groin Infections, Surgical Site Infection

Keywords

Negative Pressure Wound Therapy

Brief summary

The purpose of this randomized clinical trial is to investigate the role of negative pressure wound therapy (NPWT) vs standard sterile gauze therapy on the incidence of surgical site infections (SSI) in primarily closed groin incisions in high risk patients undergoing any open common femoral artery exposure for a vascular surgery procedure.

Detailed description

Eligible patients are randomized pre-operatively into either a standard dressing or NPWT for the groin incision. * 1 The control group receive a standard sterile gauge dressing over the groin incision. The dressing is removed on post-operative day #2 and the wound is inspected for a SSI or dehiscence, followed by daily dressing changes and wound inspections until discharge. * 2 The intervention group will receive a NPWT dressing which will be applied in the operating room under sterile conditions. The NPWT dressing will be removed on Post operative day 5. The wound is inspected for a SSI or dehiscence, followed by daily dressing changes and wound inspections until discharge.

Interventions

DEVICENegative Pressure Pressure Wound Therapy

Investigators will be using a Negative Pressure Wound Therapy Powered Suction Pump on primarily closed groin wounds after open common femoral artery exposure, The Negative pressure dressing will be applied in a sterile fashion in the operating room. The negative pressure dressing will be removed at day 5 postoperatively, or at discharge, whichever occurs first.

PROCEDUREStandard Wound Care

Standard sterile gauze coverage of the primarily closed groin wound.

Sponsors

Henry Ford Health System
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Masking description

As this intervention necessitated the use of an external negative wound therapy device, masking is not possible

Intervention model description

Patient fulfilling the inclusion criteria will be randomized into a standard gauze therapy group or a negative pressure wound therapy group.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

One or more of the following * Body Mass Index \>30 kg/m2 * Critical limb ischemia defined by Ankle Brachial Index\<0.35, rest pain, tissue loss and/or non-healing ulcers * Procedure time \>240 min * End Stage Renal Disease on dialysis * Glycated hemoglobin ≥ 8.5% * Transfusion ≥ 3 units packed Red Blood Cells * Previous femoral artery cut-down

Exclusion criteria

Any of the following * Preexisting groin infection * Complete vacuum seal cannot be achieved with negative pressure device * Allergy to Adhesive Material * Groin Surgery within last 30 days

Design outcomes

Primary

MeasureTime frameDescription
Superficial surgical site infection30 days postoperativelySurgical site infection as defined by the Center for disease control and prevention criteria

Secondary

MeasureTime frameDescription
Mortality30 daysOccurrence of mortality within 30 days of surgery
Limb Loss30 days and 1 yearOccurrence of ipsilateral limb loss SSI within 30 days and 1 year of surgery
Emergency department visit for wound complicationwithin 30 days of surgeryNumber of participants returning to the emergency department for wound complications within 30 days of surgery
Local reaction to negative wound dressing5 days postoperativelyOccurrence of a local reaction at the site of the negative pressure apparatus during application

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026